FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/An article could focus on how the CLOCK protein's role in cellular senescence and aging provides a promising target for developing new anti-aging therapies, emphasizing the potential of circadian rhythm modulation.
Retour à la bibliothèque de recherche

An article could focus on how the CLOCK protein's role in cellular senescence and aging provides a promising target for developing new anti-aging therapies, emphasizing the potential of circadian rhythm modulation.

May 16, 2026
Share

Papier source

Role of circadian CLOCK signaling in cellular senescence.

Yuan Ziyou et al.Biogerontology2025
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article décompose les résultats du papier source ci-dessus dans un langage accessible pour la communauté de recherche en peptides. Notre objectif est d'highlighter ce qui compte le plus — les implications pratiques, la force des preuves et ce que cela signifie pour la recherche en cours.

The Clockwork of Aging: How Circadian Rhythms Influence Cellular Senescence

Published: May 16, 2026 | Source: Biogerontology (2025) | Category: Peptide Therapy and Aging Research

Overview

A recent review in Biogerontology highlights the critical role of circadian rhythm regulation by the CLOCK protein in cellular senescence. This research underscores the potential for developing new anti-aging therapies that target circadian mechanisms, offering a fresh perspective on how our biological clocks influence aging at the cellular level.

Study Background

The circadian clock is an internal timekeeping system that regulates various physiological processes to align with Earth's 24-hour light-dark cycle. Disruptions in this rhythm have been linked to accelerated aging and age-related diseases such as cancer, metabolic disorders, and neurodegeneration. The CLOCK protein, a key component of the circadian machinery, has emerged as a central player in cellular senescence, which is the process by which cells lose their ability to divide and function properly.

Researchers aimed to synthesize existing knowledge on how CLOCK regulates gene transcription related to tissue homeostasis, DNA repair, and metabolism. The review also explores how disruptions in circadian rhythms due to environmental factors (like gut microbiota signals) or genetic alterations can lead to accelerated aging and cancer progression.

What the Research Found

The review reveals that CLOCK plays a dual role: it supports cellular rejuvenation by activating DNA repair mechanisms like XPA, thereby maintaining tissue health. However, in tumor cells, CLOCK signaling is often hijacked by oncogenic drivers such as c-MYC and Pdia3, which inhibit telomere shortening and cellular senescence, promoting uncontrolled cell proliferation.

Moreover, the study found that gut microbiota-derived aryl hydrocarbon receptor (AhR) signals can disrupt the CLOCK-BMAL1 complex, leading to circadian rhythm disturbances. This disruption affects autophagy regulation through interactions with mTOR and NF-κB pathways, impacting tissue function and contributing to aging-related pathologies.

What This Means for Peptide Users

While this review does not directly address peptide therapy, it provides a deeper understanding of the molecular mechanisms underlying cellular senescence. For those interested in peptides that target aging processes, such as those involved in DNA repair or metabolism regulation, these findings suggest potential new avenues for therapeutic intervention by modulating circadian rhythms.

Limitations and Caveats

As this is a review paper synthesizing existing literature rather than presenting new experimental data, the conclusions are based on previously published studies. The review does not provide novel empirical evidence but highlights gaps in our understanding of how CLOCK signaling can be therapeutically targeted to slow down aging processes. Additionally, while promising, the potential for anti-aging therapies based on circadian rhythm modulation remains speculative until further clinical trials and experimental validation.

How This Compares to Previous Research

This review builds upon earlier studies that have linked disruptions in circadian rhythms with accelerated aging and age-related diseases. However, it provides a more comprehensive analysis of how CLOCK signaling interacts with various cellular pathways to influence senescence. The dual role of CLOCK in both normal cells and tumor cells is particularly novel and offers new insights into the complex interplay between circadian regulation and cancer biology.

Our Analysis

PeptideVault's assessment of this review highlights its value as a synthesis of current knowledge on circadian rhythm regulation by CLOCK protein and its implications for aging. The paper effectively bridges gaps in understanding how disruptions in circadian rhythms contribute to cellular senescence, providing a solid foundation for future research aimed at developing anti-aging therapies.

Key Takeaways

  • CLOCK Protein's Dual Role: Understanding the dual role of CLOCK in both promoting DNA repair and supporting tumor growth provides new insights into aging mechanisms.
  • Gut Microbiota Influence: The impact of gut microbiota-derived AhR signals on circadian rhythms underscores the importance of considering environmental factors in aging research.
  • Therapeutic Potential: Modulating circadian rhythms through targeted therapies could offer a promising approach to slowing down cellular senescence and age-related diseases.

Original Source

Citation: Yuan Ziyou, Nepovimova Eugenie, Wu Qinghua et al. (2025). Role of circadian CLOCK signaling in cellular senescence.. Biogerontology. DOI: 10.1007/s10522-025-10319-7

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été préparée par l'équipe de recherche de Peptide Contacts. Nous encourageons les lecteurs à vérifier les informations auprès du papier source complet pour la méthodologie et les données complètes. L'original de la publication est disponible sur le PubMed.

Comments

Sign in to join the discussion

Cette analyse est générée à partir d'une recherche peer-reviewed pour des fins éducatives uniquement. Elle ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.